News
Article
Bausch + Lomb launches its enVista Aspire monofocal and toric IOLs in the European Union
Author(s):
Key Takeaways
- enVista Aspire IOLs offer Intermediate Optimized optics and 3C technology for enhanced depth of focus and geometric power profile harmonization.
- Higher-order aspheric coefficients on the posterior surface provide a broader range of vision compared to conventional IOLs.
The launch follows a CE Mark received late last year.
Image Martin David Harp / MJH Life Sciences
Bausch + Lomb announced the commercial launch of its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year.
According to the company, the enVista Aspire IOLs combine novel Intermediate Optimized optics, designed for a broader depth of focus, with the proven benefits of the enVista platform to “address vision needs in today’s modern, digital world.” The lens also features 3C technology (Controlled Curvature Change) which are designed to harmonize the geometric power profile outward between the central base power and power at the periphery.1,2
The company also states that unlike conventional spherical monofocal IOLs and low-order aspheric IOLs, enVista Aspire utilizes higher-order aspheric coefficients on the posterior surface of the lens for a broader range of vision.1,2
Luc Bonnefoy, president of surgical at Bausch + Lomb commented on the release of the enVista Aspire IOLs in a press release from the company.1
“Surgeons around the world have long known the benefits of the enVista platform,” said Bonnefoy, “In the US, where enVista Aspire is currently available, surgeons and their patients appreciate the features of these monofocal lenses that are designed for a broader depth of focus, and we look forward to offering that feature in Europe as part of our comprehensive IOL portfolio.”
The company also notes that the Aspire IOLs can treat astigmatism and allows surgeons to “broaden the treatable astigmatism range in cataract surgery to as low as <1.0D at the corneal plane.” In the US, it was the first and only Low-Cyl toric (1.25D) below 1.5D at the IOL plane commercially available.1,2
In October 2024, the FDA approved the enVista Envy full range of vision IOLs.
References:
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union. Press Release. Published January 13, 2025. Accessed January 13, 2025. https://www.bausch.com/news/?id=244
enVista Aspire™. Bausch + Lomb. Accessed January 13, 2025. https://www.bauschsurgical.com/cataract/enVista-Aspire/
